Vitrectomy Retinal Oxygenation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01510691|
Recruitment Status : Completed
First Posted : January 16, 2012
Last Update Posted : April 15, 2015
Vitrectomy is the common treatment for patients with macular edema secondary to epiretinal membrane. Recently, in eyes with diabetic macular edema or persistent macular edema following retinal vein occlusion, vitrectomy will be increasingly performed as an additional treatment modality. In eyes with impaired oxygen situation vitrectomy may improve the retinal oxygen saturation. However, little information is available about the oxygenation and the blood flow of the retinal vessels after vitroretinal surgery.
Hypoxia is a the major trigger of vascular endothelial growth factor (VEGF), which is in turn the most important factor for the development of macular edema. It is a major issue to improve the oxygen situation and the blood flow of the retina and there are just a few not satisfactory procedures available to overcome this problem. However, vitrectomy would be an adequate therapy for many of these diseases, and it would be an appreciated side effect of the treatment in almost every case.
To investigate the influence of oxygenation and blood flow of the retina on clinical outcomes after a successfully 23 gauge vitrectomy in eyes with epiretinal membrane, persistent macular edema following diabetic retinopathy or retinal vein occlusion.
|Condition or disease|
|Diabetic Macular Edema|
|Study Type :||Observational|
|Estimated Enrollment :||7 participants|
|Official Title:||The Influence of Retinal Oxygenation on the Clinical Outcomes in Eyes With Different Vitreoretinal Pathologies After a Successful Vitrectomy|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||March 2015|
|diabetic macular edema|
- Clinical Data [ Time Frame: 6 months ]Visus, OCT
- Blood Flow Data [ Time Frame: 6 months ]Oxygenation of retinal blood vessles and retinal blood flow
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01510691
|Department of Opthalmology/Clinical Pharmacology|
|Vienna, Austria, 1090|